Our observations thus suggest that PD-1/PD-L1 CBI may interfere with epithelial constraints on CD4+ TRM cells and unleash unrestrained TRM cell activation leading to immunopathologies like CIP, colitis, IBD, and skin inflammation, all of which may involve CD4+ T cell plasticity7–9,56,57. Here, CD274 is linked to inflammatory bowel disease.